Integrated magnetic resonance imaging and [11 C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis
- PMID: 29740862
- PMCID: PMC6105567
- DOI: 10.1002/ana.25251
Integrated magnetic resonance imaging and [11 C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis
Abstract
Objective: To characterize [11 C]-PBR28 brain uptake using positron emission tomography (PET) in people with amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS). We have previously shown increased [11 C]-PBR28 uptake in the precentral gyrus in a small group of ALS patients. Herein, we confirm our initial finding, study the longitudinal changes, and characterize the gray versus white matter distribution of [11 C]-PBR28 uptake in a larger cohort of patients with ALS and PLS.
Methods: Eighty-five participants including 53 with ALS, 11 with PLS, and 21 healthy controls underwent integrated [11 C]-PBR28 PET-magnetic resonance brain imaging. Patients were clinically assessed using the Upper Motor Neuron Burden (UMNB) and the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). [11 C]-PBR28 uptake was quantified as standardized uptake value ratio (SUVR) and compared between groups. Cortical thickness and fractional anisotropy were compared between groups and correlated with SUVR and the clinical data. [11 C]-PBR28 uptake and ALSFRS-R were compared longitudinally over 6 months in 10 ALS individuals.
Results: Whole brain voxelwise, surface-based, and region of interest analyses revealed increased [11 C]-PBR28 uptake in the precentral and paracentral gyri in ALS, and in the subcortical white matter for the same regions in PLS, compared to controls. The increase in [11 C]-PBR28 uptake colocalized and correlated with cortical thinning, reduced fractional anisotropy, and increased mean diffusivity, and correlated with higher UMNB score. No significant changes were detected in [11 C]-PBR28 uptake over 6 months despite clinical progression.
Interpretation: Glial activation measured by in vivo [11 C]-PBR28 PET is increased in pathologically relevant regions in people with ALS and correlates with clinical measures. Ann Neurol 2018;83:1186-1197.
© 2018 American Neurological Association.
Conflict of interest statement
No conflicts to report.
Figures
Similar articles
-
Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis.Neuroimage Clin. 2018 Aug 9;20:357-364. doi: 10.1016/j.nicl.2018.08.007. eCollection 2018. Neuroimage Clin. 2018. PMID: 30112276 Free PMC article.
-
Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.Neuroimage Clin. 2015 Jan 19;7:409-14. doi: 10.1016/j.nicl.2015.01.009. eCollection 2015. Neuroimage Clin. 2015. PMID: 25685708 Free PMC article.
-
Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands.J Nucl Med. 2020 Nov;61(11):1621-1627. doi: 10.2967/jnumed.119.241059. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169920 Free PMC article.
-
Neuroimaging in primary lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(sup1):18-27. doi: 10.1080/21678421.2020.1837176. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 33602015 Review.
-
Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.Neurotherapeutics. 2017 Jan;14(1):11-23. doi: 10.1007/s13311-016-0484-9. Neurotherapeutics. 2017. PMID: 27752938 Free PMC article. Review.
Cited by
-
New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases.Int J Mol Sci. 2024 Feb 26;25(5):2698. doi: 10.3390/ijms25052698. Int J Mol Sci. 2024. PMID: 38473944 Free PMC article. Review.
-
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis.BMJ. 2023 Oct 27;383:e075037. doi: 10.1136/bmj-2023-075037. BMJ. 2023. PMID: 37890889 Free PMC article. Review.
-
Treating Traumatic Brain Injury with Minocycline.Neurotherapeutics. 2023 Oct;20(6):1546-1564. doi: 10.1007/s13311-023-01426-9. Epub 2023 Sep 18. Neurotherapeutics. 2023. PMID: 37721647 Review.
-
PET and SPECT Imaging of ALS: An Educational Review.Mol Imaging. 2023 Aug 19;2023:5864391. doi: 10.1155/2023/5864391. eCollection 2023. Mol Imaging. 2023. PMID: 37636591 Free PMC article. Review.
-
Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants.Genes (Basel). 2023 Aug 21;14(8):1658. doi: 10.3390/genes14081658. Genes (Basel). 2023. PMID: 37628709 Free PMC article. Review.
References
-
- Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51(4):241–253. - PubMed
-
- Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389–1392. - PubMed
-
- Henkel JS, Beers DR, Siklos L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci. 2006;31(3):427–437. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
